Related Experiment Video

Updated: Oct 20, 2025

Murine Model of Allergen Induced Asthma
08:05

Murine Model of Allergen Induced Asthma

Published on: May 14, 2012

40.6K

Indoor Environmental Factors May Modify the Response to Mouse Allergen Reduction Among Mouse-Sensitized and Exposed

S Christy Sadreameli1, Ammara Ahmed2, Jean Curtin-Brosnan3

  • 1Eudowood Division of Pediatric Respiratory Sciences, School of Medicine, Johns Hopkins University, Baltimore, Md.

The Journal of Allergy and Clinical Immunology. in Practice
|September 10, 2021
PubMed
Abstract

Insights

Mouse allergen reduction improved asthma in children, particularly those with high initial exposure. Lower indoor particulate matter (PM10) also enhanced symptom relief. Other indoor allergens did not significantly alter these effects.

Area of Science:

  • Environmental Health
  • Allergy and Immunology
  • Pediatric Asthma

Background:

  • Effectiveness of mouse allergen reduction in children with asthma is not fully understood regarding other home exposures.
  • Investigating factors that may influence treatment outcomes is crucial for personalized asthma management.

Purpose of the Study:

  • To determine if lower baseline mouse allergen levels, reduced particulate matter 10 or less (PM10), and absence of other indoor allergen sensitization/exposure enhance asthma improvement from mouse allergen reduction.
  • To analyze the impact of these indoor factors on asthma outcomes in mouse-sensitized children.

Main Methods:

  • Secondary analysis of a randomized clinical trial involving a home mouse allergen intervention.
  • Examined the effect of baseline mouse allergen levels, indoor PM10, and other indoor allergen sensitization/exposure on asthma outcomes.

Main Results:

  • Higher baseline mouse allergen levels correlated with greater improvement in asthma symptoms and exacerbations following intervention.
  • Lower indoor PM10 levels were linked to better symptom improvement, but not exacerbation reduction.
  • Sensitization and exposure to other indoor allergens did not significantly modify the effectiveness of mouse allergen reduction.

Conclusions:

  • Mouse allergen reduction is beneficial for children with persistent asthma and mouse sensitization, especially with high baseline exposure.
  • Lower indoor PM10 levels contribute to improved asthma symptoms in this population.
Keywords:
Allergen exposureAllergen exposure reductionAllergic asthmaAllergic sensitizationPM(10)

More Related Videos

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice09:58

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice

Published on: April 13, 2010

22.7K
Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography08:58

Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography

Published on: July 10, 2018

43.4K

Related Concept Videos

Asthma-I: Introduction01:29

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.9K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
689
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
845
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
3.3K
Allergic Reactions02:06

Allergic Reactions

Overview
29.3K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
690